VivoSeq
Gastroenterology

Ulcerative Colitis (UC)

9

Pipeline Programs↗

7

Active Trials↗

5

Companies Involved↗

Ulcerative Colitis (UC) is an early-stage landscape with 9 programs across 5 companies. The most active players are Vanda Pharmaceuticals, Specialty Networks Research., Pfizer. 7 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

39/100

Pipeline Velocity

27/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

V

Vanda Pharmaceuticals

1 program

Phase 3S

Specialty Networks Research.

1 program

ApprovedPfizer logo

Pfizer

1 program

ApprovedEli Lilly logo

Eli Lilly

3 programs

ApprovedI

Innatus Therapeutics (Shanghai) Co., Ltd.

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

80%

Small molecule

4 of 5 classified programs — the dominant modality here.

20%ALL OTHERSMonoclonal antibody120%

Small molecule leads; the ring shows all 5 classified programs, each share of the total. Modality classified for 55% of 11 pipeline programs.

Analysis

Trial Status

8

clinical trials

Recruiting3 · 38%
Not yet recruiting3 · 38%
Completed1 · 13%
Enrolling by invitation1 · 13%

Clinical Trials

Trial Activity

8 trials

A Multicenter, Randomized, Open-label Clinical Study to Evaluate the Safety and Efficacy of INT-210 Capsules in Participants With Active Ulcerative Colitis
Recruiting·IInnatus Therapeutics (Shanghai) Co., Ltd.·Preclinical·NCT07692165·24 enrolled
STOpping PPI Therapy in Inactive IBD Study (STOP-IT): A Feasibility Study
Recruiting·UUniversity of Nottingham·Approved·NCT07691138·80 enrolled
A Randomized, Multicenter, Double-Blind, Placebo-Controlled Development Program to Evaluate the Efficacy and Safety of LY4268989 (MORF-057) for the Treatment of Adults With Moderately to Severely Active Ulcerative Colitis (EMERALD-3)
Recruiting·Eli Lilly logoEli Lilly·Phase 2·NCT07415044·1,431 enrolled
INSIGHT-IBD Pragmatic Study: Investigation of Mirikizumab in Real World Settings for Mirikizumab
Not yet recruiting·SSpecialty Networks Research.·Approved·NCT07686757·400 enrolled
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ponesimod in Patients With Moderately to Severely Active Ulcerative Colitis
Not yet recruiting·VVanda Pharmaceuticals·Phase 3·NCT07686081·150 enrolled
Dissecting the Complexity of Inflammatory Bowel Disease (IBD) A Prospective Study With Focus on Cardiovascular Risk
Not yet recruiting·IIRCCS Policlinico S. Donato·N/A·NCT07663201·300 enrolled
Association Between Zonulin and Lipopolysaccharide-binding Protein as Biomarkers of Intestinal Permeability and Hepatic Steatosis in Patients With Ulcerative Colitis
Enrolling by invitation·UUniversity Hospital Dubrava·N/A·NCT07662902·100 enrolled
EFFECTIVENESS AND SAFETY OF MIRIKIZUMB IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: A REAL-LIFE RETROSPECTIVE MULTICENTRE STUDY
Completed·IIRCCS San Raffaele·N/A·NCT07695636·282 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)